DERMASTRAT

Welcome to the Brand page for “DERMASTRAT”, which is offered here for Pharmaceutical preparations for the treatment of psoriasis, and pharmaceutical substances, for the prediction of response to anti-tumor necrosis factor, also known as tnf, therapies and sanitary preparations for the prediction of response to anti-tumor necrosis factor therapies; diagnostic preparations and substances for medical use; diagnostic kits consisting primarily of multiplex polymerase chain reaction reagents and biochip array reagents; clinical diagnostic preparations for medical use; clinical diagnostic reagents for medical in vitro and/or vivo use; diagnostic scanning agents for in-vivo use used for the prediction of response to anti-tumor necrosis factor therapies; diagnostic testing materials, diagnostic preparations, reagents and contrast media for medical use; clinical medical reagents; reagents for use in diagnostic tests for medical purposes; reagents for use with analyzers for medical purposes; parts and fittings for all the aforesaid goods, multiplex polymerase chain reaction reagents and biochip array reagents; chemical reagents for medical purposes; enzymes for medical purposes;chemicals used in industry, science, photography, agriculture, horticulture and forestry; chemical reagents other than for medical purpose; enzymes for scientific and research purposes and proteins for industrial use; diagnostic preparations for scientific purposes; clinical diagnostic preparations or reagents other than for medical use; diagnostic preparations, diagnostic scanning agents; diagnostic testing materials, diagnostic preparations, reagents and contrast media other than for medical use; chemical reagents for use in diagnostic tests, other than for medical use; clinical diagnostic reagents for laboratory in vitro and/or vivo use;medical services; providing health advice and information services; medical care services; health clinic services; healthcare services, geriatric health care, physical therapy; medical health assessment services, providing prediction of response to anti-tumor necrosis factor therapies; diagnostic health screening services in the field of psoriasis; medical testing for prediction of response to therapy; medical diagnostic testing services; genetic testing for medical for medical purposes; medical clinics; advice, information and consultancy services for all of the aforesaid services;scientific and technological services, research and design in the field of psoriasis; medical research services; clinical research services, conducting clinical trials for others; biological research; conducting clinical trials for others, analysis, management and reporting of clinical data; consulting services in the field of quality assessment services for clinical laboratories; chemical research; chemical laboratory services; chemical analysis; scientific and medical laboratory services for analytical testing; medical laboratory services; biochemistry research and consultant advisory services; conducting clinical trials for others; providing computer aided diagnostic testing services for predicting response to anti-tumor necrosis factor therapies for others in the field of science and research related thereto; scientific and technological services, development of test equipment for medical apparatus for others; advice, information and consultancy services relating to all the aforesaid services;.

Its status is currently believed to be active. Its class is unavailable. “DERMASTRAT” is believed to be currently owned by “Randox Laboratories Ltd”.